VolitionRx initiates second prostate cancer study assessing nucleosomics technology
VolitionRx, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ assays in detecting prostate cancer. The study is in collaboration with ImmuneHealth, a global biomarker CRO, and is taking place in Belgium.
In the prospective study, 120 blood samples will be collected from patients across four Belgian hospitals and analyzed by Belgium-based ImmuneHealth using VolitionRx's NuQ assays, which are based on the company's proprietary Nucleosomics technology. Four groups of patients will be assessed: aggressive prostate cancer, indolent prostate cancer, prostate hyperplasia and negative controls. In addition to determining the test's ability to accurately detect prostate cancer, the study will also assess the tests' ability to distinguish among the different prostate conditions and healthy samples. If the test demonstrates significant accuracy, it could have the potential to become an early-stage screening tool.
Dr. Jake Micallef, VolitionRx chief scientific officer, said, "In addition to our anaplastic prostate cancer study in collaboration with MD Anderson, we now are embarking on a pilot diagnostic prostate cancer study with ImmuneHealth of Belgium. While the anaplastic study is aimed at the differential detection of this particularly aggressive form of prostate cancer requiring very aggressive treatment, the ImmuneHealth study will investigate our NuQ assays for more general prostate cancer detection.
“Both early prostate cancer detection and selection of patients for aggressive treatment are critical for improved outcomes, which is why we are launching a second study with ImmuneHealth to further evaluate our NuQ assays in this indication,” said Micallef. “In addition, we are grateful to the Walloon region of Belgium, which is covering the majority of the costs of the study."
The NuQ tests utilize the company's proprietary Nucleosomics platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood.
In addition to this prostate cancer study, other clinical trials assessing the effectiveness of VolitionRx's assays include:
- A 4,800 patient retrospective symptomatic population study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark
- A 14,000 patient prospective screening study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark
- A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany
- A 600 patient prospective confirmatory study in lung cancer at University Hospital in Bonn, Germany
- A 250 patient prospective study in colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium
- A retrospective study with MD Anderson, Texas, to establish the efficacy of VolitionRx's NuQ tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form
- A prospective study with the University of Oxford to assess VolitionRx's NuQ tests for the diagnosis of endometriosis
- A 40 patient prospective study with Singapore General Hospital to establish the feasibility of VolitionRx's proprietary NuQ assays in detecting ovarian cancer.